Collecting tissue samples from patients with various types of lung cancer
Official title: Tissue Procurement and Natural History Study of Patients With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Run by National Institutes of Health Clinical Center (CC) · NCT02146170 · Data updated 2026-11-12
This study is collecting tissue samples from adults with different types of lung cancer to learn more about the disease and improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | May 28, 2014 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2029 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT02146170 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with confirmed diagnoses of specific lung and thymic cancers.
✕Probably not a fit
Patients with active major organ disorders or those with known HIV may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to gather tissue samples from adults diagnosed with non-small cell lung cancer, small cell lung cancer, extrapulmonary small cell cancer, pulmonary neuroendocrine tumors, and thymic epithelial tumors. Participants will undergo medical history screening, physical exams, and may provide blood, urine, saliva, and tumor biopsy samples. The collected samples will be used for in-depth genomic and proteomic analyses to enhance understanding of tumor biology and treatment responses. This research is expected to contribute to future studies on lung cancer and improve diagnostic and therapeutic strategies.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods and treatment options for lung cancer patients.
How similar studies have gone: Other studies focusing on tissue collection and molecular profiling in lung cancer have shown promise, indicating that this approach is both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: * Individuals with histologically or cytologically confirmed NSCLC, SCLC, ESCC, PNET, and TET. * Individuals consulted in the Clinical Center without a definitive diagnosis, but clinically considered likely to have a malignancy of the above histologies, pending further tissue acquisition and/or pathology review. * Age greater than or equal to18 years. Children are excluded from the study, as the above thoracic malignancies are rare in this population. * Ability of subject to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: * Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction. * Active concomitant medical or psychological illnesses that may increase the risk to the subject, at the discretion of the Principal Investigator. * Known HIV-positive individuals not on combination antiretroviral therapy are ineligible.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Arun Rajan, M.D. — National Cancer Institute (NCI)
- Study coordinator: Shannon G Swift, R.N.
- Email: shannon.swift@nih.gov
- Phone: (240) 858-3157
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
First-in-human test of HH160 in people with advanced solid tumors
HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.
-
CAIX-targeted 18F-T2 PET/CT imaging in solid tumors
This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.
-
HLX43 with Serplulimab in advanced lung cancer
This study tests whether HLX43 given with serplulimab can help adults with advanced NSCLC or SCLC who have had prior chemotherapy and immunotherapy.
-
Combination of YL201 and ivonescimab (AK112) for advanced solid tumors
This trial will test whether combining YL201 and ivonescimab (AK112) helps people with advanced solid tumors, including non‑small cell and small cell lung cancer.
-
Cirtuvivint plus irinotecan for relapsed small-cell lung cancer
This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.
-
GV20-0251 treatment for adults with advanced solid tumors
This study will test GV20-0251 to see if it helps adults with advanced solid tumors that have stopped responding to approved therapies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.